Translation

Notice: This document is an excerpt translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Tokyo, December 16, 2020
Alfresa Holdings Corporation

Notice regarding a Receipt of Indictment against a Consolidated Subsidiary Regarding a Suspected Violation of the Antimonopoly Act

Today, our Company's consolidated subsidiary, Alfresa Corporation (head office: Chiyoda-ku, Tokyo), has received an accusation lodged by the Tokyo District Public Prosecutors Office for allegedly violating the Antimonopoly Act when bidding to supply ethical pharmaceuticals ordered by the Japan Community Health care Organization (JCHO).

These developments are extremely regrettable. We sincerely apologize for the great inconvenience and concern that they may cause to our shareholders, customers, business partners, and all other stakeholders.

As reported in the release on December 14, 2020, our Company will continue to work tirelessly to ensure deeper compliance with laws and regulations, and the entire Group will do its utmost to restore the trust of stakeholders as soon as possible.